以患者为中心的结局以及达罗他胺与恩杂鲁胺之间的偏好：来自ODENZA试验的见解。 - Suppr

Suppr

超能文献

Patient-centered outcomes and preference between darolutamide and enzalutamide: insights from the ODENZA trial.

作者信息

Lim Fat Guillaume, Alibhai Shabbir

机构信息

Department of Medicine, University Health Network, University of Toronto, Toronto, Canada.

出版信息

Transl Androl Urol. 2025 May 30;14(5):1160-1164. doi: 10.21037/tau-2024-755. Epub 2025 May 27.

DOI:10.21037/tau-2024-755

PMID:40529039

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12170131/

Abstract

摘要

相似文献

Patient-centered outcomes and preference between darolutamide and enzalutamide: insights from the ODENZA trial.以患者为中心的结局以及达罗他胺与恩杂鲁胺之间的偏好：来自ODENZA试验的见解。

Transl Androl Urol. 2025 May 30;14(5):1160-1164. doi: 10.21037/tau-2024-755. Epub 2025 May 27.

A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.达洛鲁胺与恩杂鲁胺用于无症状或轻度症状性转移性去势抵抗性前列腺癌男性患者的随机、开放标签、交叉2期试验：ODENZA中的患者偏好与认知功能

Eur Urol. 2024 Mar;85(3):274-282. doi: 10.1016/j.eururo.2023.05.009. Epub 2023 Jun 2.

Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial.在健康志愿者中比较恩扎卢胺、达罗他胺和安慰剂对认知相关区域脑血流的影响：一项随机交叉试验。

Target Oncol. 2023 May;18(3):403-413. doi: 10.1007/s11523-023-00959-5. Epub 2023 Apr 27.

Darolutamide as a Second-Generation Androgen Receptor Inhibitor in the Treatment of Prostate Cancer.达洛鲁胺作为第二代雄激素受体抑制剂在前列腺癌治疗中的应用

Curr Mol Med. 2021;21(4):332-346. doi: 10.2174/1566524020666200903120344.

Synergistic combination therapy with ONC201 or ONC206, and enzalutamide or darolutamide in preclinical studies of castration-resistant prostate cancer.在去势抵抗性前列腺癌的临床前研究中，ONC201或ONC206与恩杂鲁胺或达罗他胺的协同联合治疗。

Am J Cancer Res. 2024 Dec 25;14(12):6012-6036. doi: 10.62347/VJMW4904. eCollection 2024.

Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.达罗他胺对比阿帕他胺和恩扎卢胺用于去势抵抗性前列腺癌的间接比较。

J Urol. 2021 Aug;206(2):298-307. doi: 10.1097/JU.0000000000001767. Epub 2021 Apr 5.

Cost-effectiveness of enzalutamide with androgen-deprivation therapy (ADT) versus ADT alone for the treatment of high-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer in Canada.恩杂鲁胺联合雄激素剥夺疗法（ADT）与单纯ADT治疗加拿大高危生化复发非转移性去势敏感性前列腺癌的成本效益

J Med Econ. 2025 Dec;28(1):766-777. doi: 10.1080/13696998.2025.2503660. Epub 2025 May 23.

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).迈向精准泌尿肿瘤学：利用新型抑制剂达罗他胺（ODM-201）靶向恩杂鲁胺耐药前列腺癌和雄激素受体突变体。

Eur Urol. 2018 Jan;73(1):4-8. doi: 10.1016/j.eururo.2017.08.012. Epub 2017 Aug 26.

Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.达罗他胺联合雄激素剥夺疗法用于中国高危非转移性去势抵抗性前列腺癌患者的成本-效用分析。

Adv Ther. 2023 Mar;40(3):1087-1103. doi: 10.1007/s12325-022-02389-7. Epub 2022 Dec 26.

Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.阿帕鲁胺、达罗他胺和恩扎卢胺治疗去势抵抗性前列腺癌非转移性前列腺癌的疗效比较：系统评价和网络荟萃分析。

Urol Oncol. 2020 Nov;38(11):826-834. doi: 10.1016/j.urolonc.2020.03.022. Epub 2020 Jun 28.

本文引用的文献

Establishing the minimal clinically important difference of the Brief Fatigue Inventory for brain or CNS cancer patients undergoing radiotherapy.确定接受放疗的脑癌或中枢神经系统癌患者的简明疲劳量表的最小临床重要差异。

Neurooncol Pract. 2024 Apr 27;11(5):633-639. doi: 10.1093/nop/npae034. eCollection 2024 Oct.

Does hormone therapy impact cognition in patients with prostate cancer? A systematic review and meta-analysis.激素治疗是否会影响前列腺癌患者的认知功能？系统评价和荟萃分析。

Cancer. 2024 Jun 15;130(12):2120-2138. doi: 10.1002/cncr.35210. Epub 2024 Feb 2.

Shared Decision Making in the Care of Patients With Cancer.癌症患者护理中的共同决策。

Am Soc Clin Oncol Educ Book. 2023 Jun;43:e389516. doi: 10.1200/EDBK_389516.

Eur Urol. 2024 Mar;85(3):274-282. doi: 10.1016/j.eururo.2023.05.009. Epub 2023 Jun 2.

Adherence to oral hormonal therapy in advanced prostate cancer: a scoping review.晚期前列腺癌患者口服激素治疗的依从性：一项范围综述

Ther Adv Med Oncol. 2023 Mar 29;15:17588359231152845. doi: 10.1177/17588359231152845. eCollection 2023.

Taking shared decision making for prostate cancer to the next level: Requirements for a Dutch treatment decision aid with personalized risks on side effects.将前列腺癌的共同决策提升到新高度：荷兰一款针对副作用个性化风险的治疗决策辅助工具的要求

Internet Interv. 2023 Feb 1;31:100606. doi: 10.1016/j.invent.2023.100606. eCollection 2023 Mar.

Shared decision-making as a method of care.共同决策作为一种护理方法。

BMJ Evid Based Med. 2023 Aug;28(4):213-217. doi: 10.1136/bmjebm-2022-112068. Epub 2022 Dec 2.

A Systematic Review of Patients' Values, Preferences, and Expectations for the Treatment of Metastatic Prostate Cancer.转移性前列腺癌治疗的患者价值观、偏好及期望的系统评价

Eur Urol Open Sci. 2021 Dec 20;36:9-18. doi: 10.1016/j.euros.2021.10.003. eCollection 2022 Feb.

Association of Second-generation Antiandrogens With Depression Among Patients With Prostate Cancer.第二代抗雄激素药物与前列腺癌患者抑郁的关联。

JAMA Netw Open. 2021 Dec 1;4(12):e2140803. doi: 10.1001/jamanetworkopen.2021.40803.

Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.达罗他胺与非转移性去势抵抗性前列腺癌患者的健康相关生活质量：III 期ARAMIS 试验分析。

Eur J Cancer. 2021 Sep;154:138-146. doi: 10.1016/j.ejca.2021.06.010. Epub 2021 Jul 14.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验